Meeting
2022 ASCO Annual Meeting
A phase I trial of elimusertib in combination with cisplatin or with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma.
Authors
Ryan Leibrandt
UC Davis Comprehensive Cancer Center, Sacramento, CA
Ryan Leibrandt , Paul Henry Frankel , Jan Hendrik Beumer , Naoko Takebe , Ming Yin , Hamid Emamekhoo , Primo "Lucky" N. Lara Jr., Steven Gore , Mamta Parikh
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT04491942
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS3174)
DOI
10.1200/JCO.2022.40.16_suppl.TPS3174
Abstract #
TPS3174
Poster Bd #
154a
Abstract Disclosures
Similar Posters
Poster
2015 Genitourinary Cancers Symposium
Phase I trial of gemcitabine and split-dose cisplatin plus everolimus (RAD001) in patients with advanced urothelial cancer.
First Author: Wassim Abida
Poster
2020 ASCO Virtual Scientific Program
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Jasmine Huynh
Poster
2015 ASCO Annual Meeting
Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.
First Author: Edward Jae-hoon Kim
Poster
2014 ASCO Annual Meeting
Pazopanib (P) and cisplatin (CDDP) in patients with advanced solid tumors: A UNICANCER phase I study.
First Author: Veronique Dieras